AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Lysosomal Storage Diseases

Recent research efforts aimed at curing Lysosomal Storage Diseases.

Last updated

Lysosomal Storage Diseases

Overview

Lysosomal storage diseases (LSDs) are a large group of inherited metabolic conditions in which a missing or poorly working lysosomal enzyme, transporter, or related protein prevents cells from breaking down specific materials. The resulting buildup damages organs and, in many forms, the brain and nervous system. Symptoms and prognosis vary greatly: some disorders begin in infancy and can be life-threatening within years, while others appear in adolescence or adulthood with slower progression. Common effects include developmental delay, movement problems, seizures, vision loss, enlarged organs, bone disease, heart or kidney disease, and progressive loss of independence. LSD clinical overview

Current care is disease-specific and usually aims to slow progression rather than correct the underlying mutation. Options include lifelong intravenous enzyme-replacement therapy (ERT), substrate-reduction drugs that decrease production of the stored material, pharmacological chaperones that stabilize some faulty enzymes, hematopoietic stem-cell transplantation, and supportive multidisciplinary care. These approaches have improved survival and quality of life in selected diseases, but often do not adequately treat established neurological disease because most circulating enzymes do not cross the blood–brain barrier. Clinical and therapeutic aspects Brain-delivery review

Scope of Recent Research (2020–present)

Research since 2020 has been highly active, with the central goal shifting from repeatedly supplying enzyme to enabling the body to make its own enzyme for many years or permanently. The leading questions are how to deliver treatment safely to the brain and hard-to-reach tissues, prevent immune reactions, intervene early enough to preserve neurons, and demonstrate meaningful benefit in very small patient populations. There is now an approved ex vivo gene therapy for one LSD, metachromatic leukodystrophy, but most LSDs remain at the early clinical-testing or preclinical stage rather than having a proven curative therapy. FDA approval of Lenmeldy Current and emerging therapies

Major Breakthroughs and Emerging Therapies

Gene addition and gene-modified stem cells are the most clinically advanced potentially disease-modifying strategies. In March 2024, the FDA approved atidarsagene autotemcel (Lenmeldy) for presymptomatic late-infantile and early-juvenile, and early-symptomatic early-juvenile, metachromatic leukodystrophy. The treatment collects a child’s own blood-forming stem cells, adds a functional ARSA gene with a lentiviral vector outside the body, and reinfuses the cells after chemotherapy conditioning. In long-term follow-up, treated children had substantially better survival without severe motor impairment than untreated natural-history comparators, especially when treated before symptoms or very early after onset. FDA approval of Lenmeldy Long-term MLD outcomes A similar autologous stem-cell approach for Hurler syndrome, the severe form of mucopolysaccharidosis type I (MPS I), produced supraphysiologic blood enzyme activity and clearance of storage material in an early clinical study, supporting the idea that engineered blood cells can act as durable enzyme-producing cells. Hurler stem-cell gene therapy

In vivo gene therapy uses a viral vector—most often adeno-associated virus (AAV)—to deliver a functioning gene directly into the body. In MPS VI, a phase 1/2 study of one intravenous dose of liver-directed AAV8 carrying ARSB found sustained enzyme production in the high-dose group, with no vector-attributable severe adverse events and preliminary disease stabilization after stopping ERT. Follow-up of four high-dose recipients reported sustained serum enzyme activity over a median 45 months, although one participant restarted ERT because urinary storage-material levels increased. MPS VI AAV trial Multi-year MPS VI follow-up In GM1 gangliosidosis type II, an NIH-supported phase 1/2 trial of intravenous AAV9 delivering GLB1 increased enzyme activity and lowered GM1 storage material in cerebrospinal fluid in all nine participants; brain-imaging and selected developmental measures suggested slower deterioration, but the small uncontrolled study also recorded liver-enzyme elevations in every participant and one vector-related serious adverse event. GM1 AAV9 phase 1/2 trial

Direct brain delivery and blood–brain barrier technologies seek to address the major limitation of standard ERT: inadequate treatment of the central nervous system. In late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease), direct injections of an AAV vector encoding CLN2 into multiple brain sites were associated with a slower decline in motor and language function than in natural-history cohorts, although the trial was nonrandomized and small. CLN2 intracerebral AAV study A less invasive approach is to attach enzyme to an antibody that uses a natural transport receptor at the blood–brain barrier. In a phase 1/2 MPS I study, lepunafusp alfa—iduronidase fused to an antibody against the transferrin receptor—reduced heparan sulfate in cerebrospinal fluid, an indicator consistent with enzyme delivery into the central nervous system. Lepunafusp alfa MPS I trial

Gene editing, RNA medicines, and substrate reduction remain earlier-stage approaches. Zinc-finger nuclease editing trials in MPS I and MPS II attempted to insert a working enzyme gene into the highly active albumin locus in liver cells, aiming for long-term secretion of enzyme; these studies established an important clinical precedent for in vivo editing but have not established a curative benefit. MPS II zinc-finger editing trial Newer “genetic substrate-reduction” approaches use small interfering RNA, gene editing, or related tools to reduce synthesis of the material that accumulates in cells. A 2024 systematic review found that this field was still predominantly preclinical, with relatively few animal studies and major delivery challenges. Genetic substrate-reduction review

Clinical Trials and Experimental Approaches

Notable recent clinical programs illustrate both progress and the early stage of much of the field. The National Human Genome Research Institute-supported AAV9-GLB1 program for type II GM1 gangliosidosis is a phase 1/2, open-label study with published three-year outcomes in nine children. GM1 AAV9 phase 1/2 trial Gemma Biotherapeutics’ PBGM01 program is a phase 1/2 trial delivering an AAVhu68-GLB1 vector into cerebrospinal fluid through the cisterna magna for infantile GM1 gangliosidosis; the study was active but not recruiting in its most recently posted record and has an estimated completion date in 2029. PBGM01 trial record

For neuronopathic Gaucher disease type 2, Prevail Therapeutics and collaborator Eli Lilly are studying single-dose AAV9 gene therapy LY3884961, formerly PR001, in a phase 1/2 trial that is active but not recruiting; seven infants were enrolled, with planned follow-up for safety, biomarkers, and clinical outcomes through 2028. LY3884961/PR001 trial record In Fabry disease, Zhejiang University Children’s Hospital is conducting a dose-finding study of intravenous AAV gene therapy EXG110 in up to 12 participants, measuring safety, kidney function, heart-function class, enzyme activity, and lyso-Gb3, a disease biomarker; no efficacy results had been posted in the latest trial record. EXG110 Fabry trial record

Methodologies and Scientific Approaches

Researchers combine patient-derived cells, mouse and larger-animal models, and natural-history cohorts to test whether a therapy restores enzyme activity, clears stored material, and changes functional decline. Modern studies increasingly use cerebrospinal-fluid enzyme and substrate measurements, blood biomarkers, MRI-based brain volume and myelination measures, and standardized motor, communication, and daily-function assessments. Multiplex mass-spectrometry assays using dried blood spots are also improving newborn screening and biochemical diagnosis, which is crucial because gene and cell therapies are most likely to preserve function before irreversible damage occurs. Mass-spectrometry diagnosis update Long-term MLD outcomes

The main delivery platforms are liver-targeted or nervous-system-targeted AAV vectors, lentiviral modification of a patient’s own hematopoietic stem cells, direct brain or cerebrospinal-fluid infusion, engineered enzymes that cross the blood–brain barrier, and RNA-loaded lipid nanoparticles. Researchers also use immunosuppressive regimens, antibody testing, liver monitoring, and long-term surveillance to manage immune responses to viral capsids or newly produced enzymes. MPS VI AAV trial Genetic substrate-reduction review

Leading Institutions and Funding

Major academic and clinical centers include the NIH Clinical Center and National Human Genome Research Institute, IRCCS San Raffaele Scientific Institute and Fondazione Telethon in Italy, Great Ormond Street Hospital and University College London in the United Kingdom, and specialized metabolic and transplant centers worldwide. Representative commercial and nonprofit contributors include Orchard Therapeutics, JCR Pharmaceuticals, Gemma Biotherapeutics, Prevail Therapeutics/Eli Lilly, Sanofi, and disease-specific patient foundations. GM1 AAV9 phase 1/2 trial Long-term MLD outcomes

Public funding and infrastructure remain essential because individual LSDs affect very small populations. NIH’s National Center for Advancing Translational Sciences, National Human Genome Research Institute, National Institute of Neurological Disorders and Stroke, and National Institute of Diabetes and Digestive and Kidney Diseases support rare-disease translation, the Lysosomal Disease Network, and the Ultra-Rare Gene-based Therapy program. The MPS VI AAV trial, for example, was funded by Fondazione Telethon, the European Commission Seventh Framework Programme, and the Isaac Foundation. NIH rare-disease programs MPS VI AAV trial

Strengths, Limitations, and Challenges

The strongest recent evidence is that a one-time genetic treatment can substantially alter the course of selected LSDs when delivered early, as shown by approved stem-cell gene therapy for MLD and by durable enzyme expression in early AAV studies. Treating the cause rather than repeatedly administering enzyme could reduce lifelong treatment burden and may reach tissues that conventional ERT treats poorly. FDA approval of Lenmeldy Multi-year MPS VI follow-up

However, “cure” remains an unproven label for nearly all LSDs. AAV treatment can trigger immune responses and liver inflammation, cannot currently be easily redosed after anti-vector antibodies develop, and may not reverse established brain, skeletal, or heart damage. Stem-cell gene therapy requires intensive chemotherapy conditioning and specialized transplantation infrastructure. Small, uncontrolled trials and reliance on natural-history comparisons make it difficult to separate treatment effects from disease variability, while high manufacturing costs and unequal access remain major practical barriers. GM1 AAV9 phase 1/2 trial Hurler stem-cell gene therapy Lepunafusp alfa MPS I trial

Outlook and Future Directions

LSD research is closer to durable disease modification than it was in 2020, but only MLD has a U.S.-approved gene therapy and its benefit is most compelling before major neurological decline. The milestones to watch are longer follow-up from AAV trials, confirmation of functional—not only biochemical—benefit in controlled or well-matched studies, safer redosing strategies, effective brain-wide delivery, newborn-screening expansion, and evidence that treatment begun before symptoms can prevent disability across additional disorders. Long-term MLD outcomes Current and emerging therapies

References

Don't see your disease? Request a report